EOLS Evolus, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1570562 · Fiscal year ends 12/31
Financial factors as of 2025-06-30 (2025Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY17.1%
TTM net income YoY-16.5%
TTM EPS YoY-7.8%
Revenue 3-yr CAGR28.0%
Net income 3-yr CAGR—
Margins
Gross margin67.2%
Operating margin-15.5%
Net margin-22.3%
FCF margin-15.5%
EBITDA margin-14.0%
Returns
ROE-18,729.6%
ROA-26.8%
ROIC (approx.)-61.1%
Asset turnover1.20x
Leverage & solvency
Liabilities / assets108.2%
Debt / equity—
Current ratio2.27x
Interest coverage-2.06x
Cash quality & payout
Operating cash flow / net income0.67x
Accruals ratio-8.9%
Payout ratio—
Capex / revenue0.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $297.18M | $266.27M |
| Cost of revenue | $100.07M | $83.97M |
| Gross profit | $197.11M | $182.30M |
| R&D expense | $9.58M | $9.17M |
| SG&A expense | $220.79M | $198.03M |
| Operating income | -$32.66M | -$34.41M |
| Interest expense | $19.69M | $18.73M |
| Pretax income | -$50.96M | -$49.76M |
| Income tax | $677,000 | $664,000 |
| Net income | -$51.64M | -$50.42M |
| EBITDA | -$25.16M | -$29.11M |
| EPS (basic) | -0.80 | -0.81 |
| EPS (diluted) | -0.80 | -0.81 |
| Weighted avg. shares (diluted) | 64.47M | 62.02M |
| Balance sheet | ||
| Cash & equivalents | $53.83M | $86.95M |
| Receivables | $54.70M | $47.68M |
| Inventory | $26.96M | $12.16M |
| Current assets | $142.92M | $151.34M |
| PP&E, net | $5.37M | $3.22M |
| Goodwill | $21.21M | $21.21M |
| Intangibles | $48.04M | $48.75M |
| Total assets | $225.87M | $232.57M |
| Current liabilities | $75.31M | $62.96M |
| Long-term debt | $146.10M | $121.51M |
| Total debt | $146.10M | $121.51M |
| Total liabilities | $248.97M | $227.05M |
| Shareholders' equity | -$23.11M | $5.52M |
| Net debt | $92.27M | $34.55M |
| Shares outstanding | 65.01M | 63.50M |
| Cash flow statement | ||
| Operating cash flow | -$42.27M | -$18.00M |
| Capital expenditure | $3.44M | $1.47M |
| Free cash flow | -$45.71M | -$19.47M |
| Investing cash flow | -$8.45M | -$4.82M |
| Financing cash flow | $17.34M | $47.41M |
| Depreciation & amortization | $7.51M | $5.30M |
| Stock-based compensation | $20.70M | $22.25M |
Free plan shows the latest 2 periods; Pro shows all 9 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.